Cameron Durrant, MD, DRCOG, MRCGP, MBA, FLSW, Chairman & CEO

Serial biotech experience as CEO, CFO, Chair, Exec Chair

Merck, GSK, Pharmacia, J+J

Launched 5 blockbusters during career, including antivirals

Dale Chappell, MD, MBA, Chief Scientific Officer

Founder, Black Horse Capital Advisors

Decades of biotechnology investment experience

HHMI Fellow, National Cancer Institute, Rosenberg Lab

Multiple publications in T-cell therapy, GM-CSF and immunology pathways

Timothy Morris, Chief Operating and Financial Officer

Over 36 years of professional finance and accounting experience

Over 22 years as Chief Financial Officer with public biotechnology companies (IOVA, ACRX, VVUS, QCOR)

Raised over $2 billion in equity and convertible securities for seven companies, completed four offerings for IOVA with over $1 billion in proceeds

Oversaw increase in market cap of Iovance Biotherapeutics from $550 million to $4.2 billion (7x increase)

Extensive deal experience with over 75 transactions and combined value in excess of $4 billion

Adrian Kilcoyne, MD, MBA, MPH, MFPM, MRCGP, Chief Medical Officer

Leadership experience across Medical Affairs, Evidence Generation and R&D

Over 15 years of clinical experience (AstraZeneca, Celgene, Sanofi, Roche, Baxter, Eli Lilly)

Expertise in COVID-19 and CAR-T

Directed numerous projects spanning oncology and lymphoma programs

Edward P. Jordan, MBA, Chief Commercial Officer

Over 20 years experience building and leading commercial organizations

Broad commercial experience spanning many therapeutic areas

Biotech builder with biologic experience

Extensive launch experience and builder of new therapeutic markets

DBV Technologies, AMAG, TEVA, Schering-Plough

Bob Atwill, MBA, SVP, Head of Asia-Pacific Region and Business Development

Over 30 years of executive pharma, biotech, cell therapy and healthcare experience

Corporate Officer in listed NYSE, NASDAQ, LSE, ASX and in other organisations for over 23-years

Expertise in COVID-19, GvHD, virology, I/O and cell & gene therapy

GSK, Sanofi-Synthélabo, Mesoblast and Benitec Biopharma

APAC based cross-border M&A and capital service principal with Eaton Square

Ken Trbovich, SVP, Investor Relations

20 years of experience on Wall Street as an equity analyst primarily covering biopharmaceutical companies

Research coverage included companies across multiple sectors and therapeutic areas

Analyzed more than 100 companies and published more than 2,000 reports

Royal Bank of Canada, Janney Montgomery Scott, C.E. Unterberg, Towbin (now part of Canaccord Genuity), and MLV & Co. (now part of B. Riley)